To study the impact of ABCB1 (3435C>T) gene polymorphism and combination of ABCB1 (3435C>T) and CYP3A5 (6986A>G) gene polymorphism on the efficacy of anti-asthmatic therapy in children.
Material and methods
We recruited 108 pediatric patients with bronchial asthma who underwent genotyping for polymorphic markers of ABCB1 and CYP3A5 genes. Severity of asthma was evaluated according to the GINA criteria.
ABCB1 (C3435T) genotypes occurred with a similar frequency in patients with mild, moderate or severe asthma, whereas the rate of combination of the AG genotype of CYP3A5 (6986A>G) gene and the CC genotype of ABCB1 (C3435T) gene was different in these groups of patients (p = 0.027). This combination was significantly more prevalent in patients with moderate to severe asthma compared with patients with mild asthma (p=0.019).
The combination of the AG genotype of CYP3A5 (6986A>G) gene and the CC genotype of ABCB1 (3435C>T) gene is associated with a lower efficacy of antiasthmatic therapy in children.
Bronchial asthma, anti-inflammatory therapy, pharmacogenetics, ABCB1, CYP3A5, children.